Log in

Relevant bibliographies by topics / AD non amnesico / Journal articles

To see the other types of publications on this topic, follow the link: AD non amnesico.

Journal articles on the topic 'AD non amnesico'

Author: Grafiati

Published: 9 March 2023

Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'AD non amnesico.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Souza, Leonardo Cruz de, Maxime Bertoux, Aurélie Funkiewiez, et al. "Frontal presentation of Alzheimer's disease: A series of patients with biological evidence by CSF biomarkers." Dementia & Neuropsychologia 7, no. 1 (2013): 66–74. http://dx.doi.org/10.1590/s1980-57642013dn70100011.

Full text

Abstract:

ABSTRACT Besides its typical amnesic presentation, focal atypical presentations of Alzheimer's disease (AD) have been described in neuropathological studies. These phenotypical variants of AD (so-called "atypical AD") do not follow the typical amnestic pattern and include non-amnestic focal cortical syndromes, such as posterior cortical atrophy and frontal variant AD. These variants exhibit characteristic histological lesions of Alzheimer pathology at post-mortem exam. By using physiopathological markers, such as cerebrospinal fluid markers, it is now possible to establish in vivo a biological

APA, Harvard, Vancouver, ISO, and other styles

2

Aguilar-Navarro, Sara G., Itzel I. Gonzalez-Aparicio, José Alberto Avila-Funes, Teresa Juárez-Cedillo, Teresa Tusié-Luna та Alberto Jose Mimenza-Alvarado. "Association between ApoE ε4 Carrier Status and Cardiovascular Risk Factors on Mild Cognitive Impairment among Mexican Older Adults". Brain Sciences 11, № 1 (2021): 68. http://dx.doi.org/10.3390/brainsci11010068.

Full text

Abstract:

Mild cognitive impairment (MCI) (amnestic or non-amnestic) has different clinical and neuropsychological characteristics, and its evolution is heterogeneous. Cardiovascular risk factors (CVRF), such as hypertension, diabetes, or dyslipidemia, and the presence of the Apolipoprotein E ε4 (ApoE ε4) polymorphism have been associated with an increased risk of developing Alzheimer’s disease (AD) and other dementias but the relationship is inconsistent worldwide. We aimed to establish the association between the ApoE ε4 carrier status and CVRF on MCI subtypes (amnestic and non-amnestic) in Mexican ol

APA, Harvard, Vancouver, ISO, and other styles

3

Nevzorova, K. V., Y. A. Shpilyukova, E. Yu Fedotova, A. G. Burmak, A. A. Shabalina, and S. N. Illarioshkin. "The experience of diagnosing Alzheimer’s disease based on the study of cerebrospinal fluid biomarkers." S.S. Korsakov Journal of Neurology and Psychiatry 125, no. 1 (2025): 91. https://doi.org/10.17116/jnevro202512501191.

Full text

Abstract:

Objective. To evaluate the frequency of Alzheimer’s disease (AD) confirmed by cerebrospinal fluid (CSF) biomarkers in a cohort of patients with classical (amnesic) and atypical phenotypes of this disease. Material and methods. The study included 63 patients (24 men and 39 women; median age 65 years [60; 71]). All patients were divided into 3 groups according to the phenotype: a classic amnesic phenotype (n=32), frequent non-amnesic phenotypes (n=21) and rare non-amnesic phenotypes (n=10). All patients underwent lumbar puncture followed by the CSF biomarkers evaluation (beta-amyloid 1—42 (Aβ1—4

APA, Harvard, Vancouver, ISO, and other styles

4

Putcha, Deepti, Nicole Carvalho, Sheena Dev, Scott M. McGinnis, Bradford C. Dickerson, and Bonnie Wong. "Verbal Encoding Deficits Impact Recognition Memory in Atypical “Non-Amnestic” Alzheimer’s Disease." Brain Sciences 12, no. 7 (2022): 843. http://dx.doi.org/10.3390/brainsci12070843.

Full text

Abstract:

Memory encoding and retrieval deficits have been identified in atypical Alzheimer’s disease (AD), including posterior cortical atrophy (PCA) and logopenic variant primary progressive aphasia (lvPPA), despite these groups being referred to as “non-amnestic”. There is a critical need to better understand recognition memory in atypical AD. We investigated performance on the California Verbal Learning Test (CVLT-II-SF) in 23 amyloid-positive, tau-positive, and neurodegeneration-positive participants with atypical “non-amnestic” variants of AD (14 PCA, 9 lvPPA) and 14 amnestic AD participants. Reco

APA, Harvard, Vancouver, ISO, and other styles

5

Bergeron, David, Jean-Mathieu Beauregard, Jean-Guimond, et al. "Posterior Cingulate Cortex Hypometabolism in Non-Amnestic Variants of Alzheimer’s Disease." Journal of Alzheimer's Disease 77, no. 4 (2020): 1569–77. http://dx.doi.org/10.3233/jad-200567.

Full text

Abstract:

Background: Hypometabolism of the posterior cingulate cortex (PCC) is an important diagnostic feature of late-onset, amnestic Alzheimer’s disease (AD) measured with 18F-fluorodeoxyglucose positron emission tomography (FDG-PET). However, it is unclear whether PCC hypometabolism has diagnostic value in young-onset, non-amnestic variants of AD, which exhibit less pathology in the hippocampus and default mode network. Objective: Evaluate the prevalence and diagnostic value of PCC hypometabolism in non-amnestic variants of AD. Methods: We retrospectively identified 60 patients with young-onset, aty

APA, Harvard, Vancouver, ISO, and other styles

6

Polden, Megan, and Trevor J. Crawford. "Eye Movement Latency Coefficient of Variation as a Predictor of Cognitive Impairment: An Eye Tracking Study of Cognitive Impairment." Vision 7, no. 2 (2023): 38. http://dx.doi.org/10.3390/vision7020038.

Full text

Abstract:

Studies demonstrated impairment in the control of saccadic eye movements in Alzheimer’s disease (AD) and people with mild cognitive impairment (MCI) when conducting the pro-saccade and antisaccade tasks. Research showed that changes in the pro and antisaccade latencies may be particularly sensitive to dementia and general executive functioning. These tasks show potential for diagnostic use, as they provide a rich set of potential eye tracking markers. One such marker, the coefficient of variation (CV), is so far overlooked. For biological markers to be reliable, they must be able to detect abn

APA, Harvard, Vancouver, ISO, and other styles

7

Becker, James T., Olurotimi Bajulaiye, and Christine Smith. "Longitudinal analysis of a two-component model of the memory deficit in Alzheimer's disease." Psychological Medicine 22, no. 2 (1992): 437–45. http://dx.doi.org/10.1017/s0033291700030385.

Full text

Abstract:

SYNOPSISThe memory deficit in Alzheimer's disease (AD) has been characterized as consisting of multiple components. The purpose of this study was to confirm the utility of a two-process model, and to examine changes in the nature and extent of the neuropsychological deficits after a one-year interval. The results replicate the initial observation that the memory loss in AD can be described as consisting of a focal amnesic syndrome and a dysexecutive syndrome characterized by failure of rapid information processing and search of both episodic and semantic memory. One year after the initial obse

APA, Harvard, Vancouver, ISO, and other styles

8

Xue, Xiaofan, Shanshan Mei, Anqi Huang, et al. "Alzheimer’s Disease Related Biomarkers Were Associated with Amnestic Cognitive Impairment in Parkinson’s Disease: A Cross-Sectional Cohort Study." Brain Sciences 14, no. 8 (2024): 787. http://dx.doi.org/10.3390/brainsci14080787.

Full text

Abstract:

Background: Cognitive impairment is common in patients with Parkinson’s disease (PD) and occurs through multiple mechanisms, including Alzheimer’s disease (AD) pathology and the involvement of α-synucleinopathies. We aimed to investigate the pathological biomarkers of both PD and AD in plasma and neuronal extracellular vesicles (EVs) and their association with different types of cognitive impairment in PD patients. Methods: A total of 122 patients with PD and 30 healthy controls were included in this cross-sectional cohort study between March 2021 and July 2023. Non-dementia PD patients were d

APA, Harvard, Vancouver, ISO, and other styles

9

Andrejeva, Nadeshda, Maren Knebel, Vasco Dos Santos, et al. "Neurocognitive Deficits and Effects of Cognitive Reserve in Mild Cognitive Impairment." Dementia and Geriatric Cognitive Disorders 41, no. 3-4 (2016): 199–209. http://dx.doi.org/10.1159/000443791.

Full text

Abstract:

Background/Aims: Mild cognitive impairment (MCI) is a frequent syndrome in the older population, which involves an increased risk to develop Alzheimer's disease (AD). The latter can be modified by the cognitive reserve, which can be operationalized by the length of school education. MCI can be differentiated into four subtypes according to the cognitive domains involved: amnestic MCI, multiple-domain amnestic MCI, non-amnestic MCI and multiple-domain non-amnestic MCI. While neurocognitive deficits are a constituent of the diagnosis of these subtypes, the question of how they refer to the cogni

APA, Harvard, Vancouver, ISO, and other styles

10

Bairami, Styliani, Vasiliki Folia, Ioannis Liampas, et al. "Exploring Verbal Fluency Strategies among Individuals with Normal Cognition, Amnestic and Non-Amnestic Mild Cognitive Impairment, and Alzheimer’s Disease." Medicina 59, no. 10 (2023): 1860. http://dx.doi.org/10.3390/medicina59101860.

Full text

Abstract:

Background and Objectives: The present study explored the utilization of verbal fluency (VF) cognitive strategies, including clustering, switching, intrusions, and perseverations, within both semantic (SVF) and phonemic (PVF) conditions, across a continuum of neurocognitive decline, spanning from normal cognitive ageing (NC) to mild cognitive impairment (MCI) and its subtypes, amnestic (aMCI) and non-amnestic (naMCI), as well as AD. Materials and Methods: The study sample was derived from the Hellenic Longitudinal Investigation of Aging and Diet (HELIAD) cohort. The sample included 1607 NC ind

APA, Harvard, Vancouver, ISO, and other styles

11

Jungwirth, S., S. Zehetmayer, M. Hinterberger, K. H. Tragl, and P. Fischer. "The validity of amnestic MCI and non-amnestic MCI at age 75 in the prediction of Alzheimer's dementia and vascular dementia." International Psychogeriatrics 24, no. 6 (2012): 959–66. http://dx.doi.org/10.1017/s1041610211002870.

Full text

Abstract:

ABSTRACTBackground: Clinical subtypes of mild cognitive impairment (MCI) were assigned as potential prodromes to various types of dementia. Amnestic MCI (aMCI) is said to have a high likelihood of progressing to Alzheimer's dementia (AD) and non-amnestic MCI (naMCI) subtypes are assumed to have a higher likelihood of progressing to non-AD dementia. The aim of this study was to investigate the prognostic accuracy of aMCI and naMCI for the development of AD, vascular dementia (VaD), and mixed dementia.Methods: In this longitudinal study, 487 subjects without dementia (cognitively healthy: n = 38

APA, Harvard, Vancouver, ISO, and other styles

12

Smith, Alphonso, James E. Eaton, and Richard R. Darby. "A-252 A Suspected Case Of Limbic-Predominant Age-Related TDP-43 Encephalopathy (LATE) in an Older Adult." Archives of Clinical Neuropsychology 37, no. 6 (2022): 1396. http://dx.doi.org/10.1093/arclin/acac060.252.

Full text

Abstract:

Abstract Objective: LATE is a common but underrecognized neuropathology that causes a progressive amnestic syndrome in older adults which mimics an Alzheimer’s disease (AD) clinical profile. Method: A 75-year-old female with a history of progressive cognitive impairment presented to a multidisciplinary neurology clinic. Neurocognitive screening during her neurological exam showed an amnestic memory profile. A work-up for medical causes for her cognitive impairment was negative. She had prominent hippocampal atrophy on MRI with a negative amyloid PET scan, raising concerns for LATE. She was ref

APA, Harvard, Vancouver, ISO, and other styles

13

Lehmann, Sylvain, Susanna Schraen-Maschke, Jean-Sébastien Vidal, et al. "Blood Neurofilament Levels Predict Cognitive Decline across the Alzheimer’s Disease Continuum." International Journal of Molecular Sciences 24, no. 24 (2023): 17361. http://dx.doi.org/10.3390/ijms242417361.

Full text

Abstract:

Neurofilament light chain (NfL) is a potential diagnostic and prognostic plasma biomarker for numerous neurological diseases including Alzheimer’s disease (AD). In this study, we investigated the relationship between baseline plasma concentration of Nfl and Mild Cognitive Impairment in participants who did and did not have a clinically determined diagnosis of dementia by the end of the three-year study. Additionally, we explored the connection between baseline plasma concentration of NfL and AD dementia patients, considering their demographics, clinical features, and cognitive profiles. A tota

APA, Harvard, Vancouver, ISO, and other styles

14

Voskou, Panagiota. "501 - Prediction of Mild Cognitive Impairment (MCI) progression to Alzheimer Disease (AD) or Dementia with Lewy Bodies (DLB): Is this possible neuropsychologically?" International Psychogeriatrics 33, S1 (2021): 55–56. http://dx.doi.org/10.1017/s1041610221001964.

Full text

Abstract:

Objective:Aim of the present review study was to describe and compare the neurocognitive features of MCI which could predict its progression to DLB vs AD.Background:Progression of MCI to AD or DLB is a relatively recent field of study with emphasis on the clinical or neuropsychological features of MCI which could potentially predict its progression to specific types of dementia.Methods:A literature review in the Pubmed database has been made, after the year 2005, using the key- words: neuropsychological assessment; MCI; AD; DLB; progression to dementia. Seventeen relevant articles have been fo

APA, Harvard, Vancouver, ISO, and other styles

15

Collins, Kathleen, Brittany Rohl, Sarah Morgan, Edward D. Huey, Elan D. Louis, and Stephanie Cosentino. "Mild Cognitive Impairment Subtypes in a Cohort of Elderly Essential Tremor Cases." Journal of the International Neuropsychological Society 23, no. 5 (2017): 390–99. http://dx.doi.org/10.1017/s1355617717000170.

Full text

Abstract:

AbstractObjectivesIndividuals with essential tremor (ET) exhibit a range of cognitive deficits generally conceptualized as “dysexecutive” or “fronto-subcortical,” and thought to reflect disrupted cortico-cerebellar networks. In light of emerging evidence that ET increases risk for Alzheimer’s disease (AD), it is critical to more closely examine the nature of specific cognitive deficits in ET, with particular attention to amnestic deficits that may signal early AD.MethodsWe performed a cross-sectional analysis of baseline data from 128 ET cases (age 80.4±9.5 years) enrolled in a longitudinal, c

APA, Harvard, Vancouver, ISO, and other styles

16

Wang, Siyu. "Progress in Alzheimer's disease and treatment." Theoretical and Natural Science 65, no. 1 (2024): 131–35. https://doi.org/10.54254/2753-8818/2024.la18096.

Full text

Abstract:

Alzheimer's disease has a large disease burden on middle-aged and elderly people, and has become an important disease of clinical concern. At present, the incidence of Alzheimer's disease in China is relatively high, and the incidence rate is relatively high in the world. AD is a neurodegenerative disease that is related with -amyloid-containing plaques and tau-containing neurofibrillary tangles. Its symptoms include amnestic cognitive impairment and non-amnestic cognitive impairment. The curing of AD now mainly relies on NMDA receptor antagonists and Cholinesterase inhibitors. Recent research

APA, Harvard, Vancouver, ISO, and other styles

17

Souza, Leonardo Cruz de, Luciano Inácio Mariano, Renata Freire de Moraes, and Paulo Caramelli. "Behavioral variant of frontotemporal dementia or frontal variant of Alzheimer's disease? A case study." Dementia & Neuropsychologia 13, no. 3 (2019): 356–60. http://dx.doi.org/10.1590/1980-57642018dn13-030015.

Full text

Abstract:

ABSTRACT Alzheimer's disease (AD) has heterogeneous clinical presentations. Amnestic progressive disorder leading to dementia is the most typical, but non-amnestic presentations are also recognized. Here we report a case of frontal variant of AD. A right-handed woman, aged 68 years, was referred for progressive behavioral disorders and personality changes. She had a corroborated history of dietary changes, hyperorality, impulsivity, affective indifference and apathy, with functional impairment. Cognitive assessment yielded severe executive deficits. Positron emission tomography with fluorodeox

APA, Harvard, Vancouver, ISO, and other styles

18

Biundo, Roberta, Simona Gardini, Paolo Caffarra, et al. "Influence of APOE Status on Lexical–Semantic Skills in Mild Cognitive Impairment." Journal of the International Neuropsychological Society 17, no. 3 (2011): 423–30. http://dx.doi.org/10.1017/s135561771100021x.

Full text

Abstract:

AbstractThis study characterized the relationship between apolipoprotein E (APOE) status and residual semantic abilities in amnestic mild cognitive impairment (MCI). APOE status (ε4 carrier/non ε4 carrier) was determined in 30 amnestic MCIs and in 22 healthy matched non ε4 carrier controls. The lexical characteristics (age of acquisition, typicality, familiarity) of words produced in a category fluency task were determined. MCIs produced fewer words than controls and these were also earlier acquired and more familiar. The words produced by MCI ε4 carriers were earlier acquired than those of no

APA, Harvard, Vancouver, ISO, and other styles

19

Li, Esther, Christine Walsh, Leslie Yack, et al. "0042 Rest-activity-patterns and Daytime Napping Differ Across Alzheimer’s Disease Phenotypes." SLEEP 48, Supplement_1 (2025): A18—A19. https://doi.org/10.1093/sleep/zsaf090.0042.

Full text

Abstract:

Abstract Introduction Sleep disruption in Alzheimer’s disease (AD) is common, linked to cognitive decline, and a major cause of institutionalization. While AD is associated with increased daytime napping, nocturnal wakefulness, and disrupted rest-activity rhythms (RAR), differences between amnestic (amAD) and atypical (atypAD; non-amnestic presentation) phenotypes remain underexplored. Our goal is to assess daytime napping and RAR across AD phenotypes: amnestic AD (amAD) and atypical AD (atypAD; non-amnestic presentation). Since sleep disturbances in amAD involves increased nocturnal awakening

APA, Harvard, Vancouver, ISO, and other styles

20

Weston, PSJ, RW Paterson, M. Lehmann, et al. "USING FLORBETAPIR PET TO INCREASE DIAGNOSTIC CERTAINTY IN ATYPICAL DEMENTIAS." Journal of Neurology, Neurosurgery & Psychiatry 86, no. 11 (2015): e4.112-e4. http://dx.doi.org/10.1136/jnnp-2015-312379.24.

Full text

Abstract:

Amyloid PET or CSF can be used to determine Alzheimer pathology in vivo. Few studies have assessed the additional value of amyloid imaging where CSF results are equivocal. We recruited 20 cognitive patients (65.5+/–7.6 y) with MRI, neuropsychology, and CSF Aβ1–42 and tau measured during their diagnostic assessment. Individuals were selected to have a range of CSF results; ten had amnestic and ten non-amnestic presentations. Following the investigations, the treating neurologist gave a diagnosis (AD or non-AD). Four controls (63+/–7.0y) also had CSF examination. All subjects had Florbetapir PET

APA, Harvard, Vancouver, ISO, and other styles

21

Paraskevas, George P., Vasilios C. Constantinides, Fotini Boufidou, et al. "Recognizing Atypical Presentations of Alzheimer’s Disease: The Importance of CSF Biomarkers in Clinical Practice." Diagnostics 12, no. 12 (2022): 3011. http://dx.doi.org/10.3390/diagnostics12123011.

Full text

Abstract:

Besides the typical amnestic presentation, neuropathological studies indicate that Alzheimer’s disease (AD) may present with atypical clinical pictures. The relative frequencies of typical and atypical or mixed presentations within the entire spectrum of AD remain unclear, while some mixed or atypical presentations may have not received adequate attention for them to be included in diagnostic criteria. We investigated the spectrum of clinical presentations in patients with the AD CSF biomarker profile (high tau and phospho-tau, low Aβ42 levels), hospitalized in a tertiary academic center. Amon

APA, Harvard, Vancouver, ISO, and other styles

22

Dolphin, H., A. Fallon, C. McHale, et al. "89 CSF BIOMARKER UTILITY IN SUPPORTING ALZHEIMER’S DISEASE DIAGNOSIS: CLINICAL PERSPECTIVES FROM AN IRISH REGIONAL SPECIALIST MEMORY SERVICE." Age and Ageing 50, Supplement_3 (2021): ii9—ii41. http://dx.doi.org/10.1093/ageing/afab219.89.

Full text

Abstract:

Abstract Background CSF (cerebrospinal fluid) biomarkers [amyloid- beta-42 (AB-42), phosphorylated tau (p-tau)] are increasingly used in supporting clinical diagnosis of Alzheimer’s Disease (AD). Both elevated CSF p-tau and reduced AB-42 are necessary for pathological diagnosis of AD. The aim of this study is to apply recent international recommendations to patients attending a regional specialist memory service, evaluating consistency with detailed clinical, neuroimaging, and neuropsychological ad-phenotype profiling. Methods All patients age &lt; 80, with mild/subjective cognitive and/or

APA, Harvard, Vancouver, ISO, and other styles

23

Tahmasebi, R., S. Zehetmayer, G. Pusswald, G. Kovacs, E. Stögmann, and J. Lehrner. "Identification of odors, faces, cities and naming of objects in patients with subjective cognitive decline, mild cognitive impairment and Alzheimer´s disease: a longitudinal study." International Psychogeriatrics 31, no. 04 (2018): 537–49. http://dx.doi.org/10.1017/s1041610218001114.

Full text

Abstract:

ABSTRACTObjective:Recent studies have tried to find a reliable way of predicting the development of Alzheimer´s Disease (AD) among patients with mild cognitive impairment (MCI), often focusing on olfactory dysfunction or semantic memory. Our study aimed to validate these findings while also comparing the predictive accuracy of olfactory and semantic assessments for this purpose.Method:Six hundred fifty patients (median age 68, 58% females) including controls, SCD (subjective cognitive decline), non-amnestic MCI (naMCI), amnestic MCI (aMCI), and AD patients were tested for olfactory dysfunction

APA, Harvard, Vancouver, ISO, and other styles

24

Perrin, Cameron K., Amanda Cook Maher, Allyson Gregoire, et al. "77 Differentiating Amnestic Versus Non-Amnestic Mild Cognitive Impairment Using the NIH Toolbox Cognition Battery." Journal of the International Neuropsychological Society 29, s1 (2023): 380–81. http://dx.doi.org/10.1017/s1355617723005131.

Full text

Abstract:

Objective:In research, and particularly clinical trials, it is important to identify persons at high risk for developing Alzheimer’s Disease (AD), such as those with Mild Cognitive Impairment (MCI). However, not all persons with this diagnosis have a high risk of AD as MCI can be broken down further into amnestic MCI (aMCI), who have a high risk specifically for AD, and non-amnestic MCI (naMCI), who are predominantly at risk for other dementias. People with aMCI largely differ from healthy controls and naMCI on memory tasks as it is the hallmark criteria for an amnestic diagnosis. Given the gr

APA, Harvard, Vancouver, ISO, and other styles

25

Schaefer, Sydney Y., Michael Malek-Ahmadi, Andrew Hooyman, Jace B. King, and Kevin Duff. "Association Between Motor Task Performance and Hippocampal Atrophy Across Cognitively Unimpaired, Amnestic Mild Cognitive Impairment, and Alzheimer’s Disease Individuals." Journal of Alzheimer's Disease 85, no. 4 (2022): 1411–17. http://dx.doi.org/10.3233/jad-210665.

Full text

Abstract:

Hippocampal atrophy is a widely used biomarker for Alzheimer’s disease (AD), but the cost, time, and contraindications associated with magnetic resonance imaging (MRI) limit its use. Recent work has shown that a low-cost upper extremity motor task has potential in identifying AD risk. Fifty-four older adults (15 cognitively unimpaired, 24 amnestic mild cognitive impairment, and 15 AD) completed six motor task trials and a structural MRI. Several measures of motor task performance significantly predicted bilateral hippocampal volume, controlling for age, sex, education, and memory. Thus, this m

APA, Harvard, Vancouver, ISO, and other styles

26

Balthazar, Marcio Luiz Figueredo, and Benito Pereira Damasceno. "Dysexecutive mild cognitive impairment associated to frontal atrophy: Case report." Dementia & Neuropsychologia 2, no. 1 (2008): 76–79. http://dx.doi.org/10.1590/s1980-57642009dn20100015.

Full text

Abstract:

Abstract Non-amnestic mild cognitive impairment (MCI) evolving to neurodegenerative diseases other than Alzheimer's disease (AD) is rarely well documented. We report a case of a 49 year-old woman who presented a slowly progressive attentional/dysexecutive syndrome sparing other cognitive domains and without significant impairment of daily life activities. Her mother had Parkinsonism and her brother, a psychotic syndrome. Brain CT/MRI showed frontal atrophy while brain SPECT showed moderate cortical hypoperfusion, mainly in the frontal lobes. Our case is an example of non-memory MCI whose neuro

APA, Harvard, Vancouver, ISO, and other styles

27

Sundermann, Erin E., Lisa L. Barnes, Mark W. Bondi, David A. Bennett, David P. Salmon, and Pauline M. Maki. "Improving Detection of Amnestic Mild Cognitive Impairment with Sex-Specific Cognitive Norms." Journal of Alzheimer's Disease 84, no. 4 (2021): 1763–70. http://dx.doi.org/10.3233/jad-215260.

Full text

Abstract:

Background Despite a female advantage in verbal memory, normative data for verbal memory tests used to diagnose Alzheimer’s disease (AD) dementia and amnestic mild cognitive impairment (aMCI) often are not sex-adjusted. Objective To determine whether sex-adjusted norms improve aMCI diagnostic accuracy when accuracy was evaluated by progression to AD dementia over time. Methods Non-sex-specific and sex-specific verbal memory test norms were incorporated into Jak/Bondi aMCI criteria and applied to older (age 65–90) non-demented women (N = 1,036) and men (N = 355) from the Rush Memory and Aging P

APA, Harvard, Vancouver, ISO, and other styles

28

Ramanan, Vijay K., and Jonathan Graff-Radford. "LATE, Hippocampal Sclerosis, and Primary Age-related Tauopathy." CONTINUUM: Lifelong Learning in Neurology 30, no. 6 (2024): 1726–43. https://doi.org/10.1212/con.0000000000001499.

Full text

Abstract:

ABSTRACT OBJECTIVE Although Alzheimer disease (AD) is the most common neurodegenerative cause of dementia, neurologists must be aware of other etiologies that can mimic the amnestic-predominant syndrome and medial temporal brain involvement typically associated with AD. This article reviews recent updates surrounding limbic-predominant age-related transactive response DNA-binding protein 43 (TDP-43) encephalopathy (LATE), hippocampal sclerosis, and primary age-related tauopathy. LATEST DEVELOPMENTS LATE neuropathologic change occurs in approximately 40% of autopsied older adults, including occ

APA, Harvard, Vancouver, ISO, and other styles

29

Meilan, Juan J. G., Francisco Martinez-Sanchez, Juan Carro, Nuria Carcavilla, and Olga Ivanova. "Voice Markers of Lexical Access in Mild Cognitive Impairment and Alzheimer's Disease." Current Alzheimer Research 15, no. 2 (2018): 111–19. http://dx.doi.org/10.2174/1567205014666170829112439.

Full text

Abstract:

Background: Recent studies have identified the correlation between dementia and certain vocal features, such as voice and speech changes. Vocal features may act as early markers of Alzheimer's disease (AD). Despite being present in non-pathological senescence and Mild Cognitive Impairment, especially in its amnesic subtype (aMCI), these voice- and speech-related symptoms are the first signs of AD. The purpose of this study is to verify whether these signs are related to deficits in lexical access, which appear early in AD. Method: Anomic deficits in persons with MCI and AD are assessed through

APA, Harvard, Vancouver, ISO, and other styles

30

Vandiver, Richard, Michael J. Lyons, and Kristy Cuthbert. "RELATION BETWEEN ERECTILE DYSFUNCTION AND AMNESTIC MILD COGNITIVE IMPAIRMENT ACROSS TWO TIME POINTS." Innovation in Aging 3, Supplement_1 (2019): S958. http://dx.doi.org/10.1093/geroni/igz038.3476.

Full text

Abstract:

Abstract Previous research by the Vietnam Era Twin Study of Aging (VETSA) demonstrated an association between erectile dysfunction (ED) and cognitive functioning. That finding supports a hypothesis that cardiovascular dysfunction may underlie both ED and problems in cognitive functioning. The purpose of the current research was to extend these findings by investigating a putative association between ED and amnestic and non-amnestic mild cognitive impairment (MCI). MCI is of particular interest because of its relationship with Alzheimer’s disease and other dementing illnesses. VETSA is a longit

APA, Harvard, Vancouver, ISO, and other styles

31

Forlenza, Orestes Vicente, Breno Satler Diniz, Paula Villela Nunes, Claudia Maia Memória, Monica Sanches Yassuda, and Wagner Farid Gattaz. "Diagnostic transitions in mild cognitive impairment subtypes." International Psychogeriatrics 21, no. 6 (2009): 1088–95. http://dx.doi.org/10.1017/s1041610209990792.

Full text

Abstract:

ABSTRACTBackground: At least for a subset of patients, the clinical diagnosis of mild cognitive impairment (MCI) may represent an intermediate stage between normal aging and dementia. Nevertheless, the patterns of transition of cognitive states between normal cognitive aging and MCI to dementia are not well established. In this study we address the pattern of transitions between cognitive states in patients with MCI and healthy controls, prior to the conversion to dementia.Methods: 139 subjects (78% women, mean age, 68.5 ± 6.1 years; mean educational level, 11.7 ± 5.4 years) were consecutively

APA, Harvard, Vancouver, ISO, and other styles

32

Kim, Heeyoung, Sungmin Jun, Bum Soo Kim, and In-Joo Kim. "Serum Adiponectin in Alzheimer’s Disease (AD): Association with AD Biomarkers and Cognitive Outcome." Journal of Alzheimer's Disease 84, no. 3 (2021): 1163–72. http://dx.doi.org/10.3233/jad-210722.

Full text

Abstract:

Background: The association between dementia and serum adiponectin has been evaluated in many studies; however, conclusions remain mixed. Objective: We investigated the cross-sectional associations of adiponectin with cognitive function and Alzheimer’s disease (AD) biomarkers and whether serum adiponectin levels can predict cognitive outcomes. Methods: This study included 496 participants from the Alzheimer’s Disease Neuroimaging Initiative 1 (ADNI1) with available serum adiponectin levels at baseline and ≥65 years of age. Subjects were stratified based on sex and apolipoprotein ɛ4 (APOE4) car

APA, Harvard, Vancouver, ISO, and other styles

33

Cerman, Jiri, Ross Andel, Jan Laczo, et al. "Subjective Spatial Navigation Complaints - A Frequent Symptom Reported by Patients with Subjective Cognitive Decline, Mild Cognitive Impairment and Alzheimer's Disease." Current Alzheimer Research 15, no. 3 (2018): 219–28. http://dx.doi.org/10.2174/1567205014666171120145349.

Full text

Abstract:

Background: Great effort has been put into developing simple and feasible tools capable to detect Alzheimer's disease (AD) in its early clinical stage. Spatial navigation impairment occurs very early in AD and is detectable even in the stage of mild cognitive impairment (MCI). Objective: The aim was to describe the frequency of self-reported spatial navigation complaints in patients with subjective cognitive decline (SCD), amnestic and non-amnestic MCI (aMCI, naMCI) and AD dementia and to assess whether a simple questionnaire based on these complaints may be used to detect early AD. Method: In

APA, Harvard, Vancouver, ISO, and other styles

34

Paraskevas, George P., and Elisabeth Kapaki. "Cerebrospinal Fluid Biomarkers for Alzheimer’s Disease in the Era of Disease-Modifying Treatments." Brain Sciences 11, no. 10 (2021): 1258. http://dx.doi.org/10.3390/brainsci11101258.

Full text

Abstract:

Correct in vivo diagnosis of Alzheimer’s disease (AD) helps to avoid administration of disease-modifying treatments in non-AD patients, and allows the possible use of such treatments in clinically atypical AD patients. Cerebrospinal fluid (CSF) biomarkers offer a tool for AD diagnosis. A reduction in CSF β-amyloid (marker of amyloid plaque burden), although compatible with Alzheimer’s pathological change, may also be observed in other dementing disorders, including vascular cognitive disorders due to subcortical small-vessel disease, dementia with Lewy bodies and normal-pressure hydrocephalus.

APA, Harvard, Vancouver, ISO, and other styles

35

Parfenov, V. A., D. A. Grishina, A. B. Lokshina, V. V. Grinyuk, V. V. Zakharov, and K. V. Shevtsova. "Mild cognitive impairment due to cerebrovascular disease and Alzheimer’s." Neurology, Neuropsychiatry, Psychosomatics 17, no. 3 (2025): 77–83. https://doi.org/10.14412/2074-2711-2025-3-77-83.

Full text

Abstract:

Cognitive impairment (CI) is one of the most common causes of disability in the elderly. For several years before dementia develops, it is often preceded by mild cognitive impairment (MCI), which is characterized by reduced memory and/or other cognitive functions without significant decline in daily activities. The most common causes of MCI are Alzheimer’s disease (AD), cerebrovascular disease, or a combination of both. Vascular cognitive impairment caused by cerebral microangiopathy is typically represented by non-amnestic MCI subtypes, whereas AD usually presents as a single-domain amnestic

APA, Harvard, Vancouver, ISO, and other styles

36

Evans, Sarah A., Elizabeth R. Paitel, Riya Bhasin, and Kristy A. Nielson. "Genetic Risk for Alzheimer’s Disease Alters Perceived Executive Dysfunction in Cognitively Healthy Middle-Aged and Older Adults." Journal of Alzheimer's Disease Reports 8, no. 1 (2024): 267–79. http://dx.doi.org/10.3233/adr-230166.

Full text

Abstract:

Background: Subjective cognitive complaints (SCC) may be an early indicator of future cognitive decline. However, findings comparing SCC and objective cognitive performance have varied, particularly in the memory domain. Even less well established is the relationship between subjective and objective complaints in non-amnestic domains, such as in executive functioning, despite evidence indicating very early changes in these domains. Moreover, particularly early changes in both amnestic and non-amnestic domains are apparent in those carrying the Apolipoprotein-E ɛ4 allele, a primary genetic risk

APA, Harvard, Vancouver, ISO, and other styles

37

Lee, Sun Hyung, Jun Ho Lee, Min Soo Byun, et al. "Comparison of Amyloid Positivity Rate and Accumulation Pattern between Amnestic and Non-Amnestic Type Mild Cognitive Impairment." Psychiatry Investigation 17, no. 6 (2020): 603–7. http://dx.doi.org/10.30773/pi.2020.0063.

Full text

Abstract:

Objective We aimed to compare cerebral beta-amyloid protein (Aβ) positivity rate and amyloid accumulation pattern on amyloid positron emission tomography (PET) between mild cognitive impairment (MCI) subtypes, i.e. amnestic mild cognitive impairment (aMCI) and non-amnestic mild cognitive impairment (naMCI).Methods The study participants were 34 naMCI patients and age-, sex- and education-matched 68 aMCI patients (1:2 ratio) who visited the Dementia and Age-Associated Cognitive Decline Clinic of the Seoul National University Hospital. All participants received comprehensive clinical and neurops

APA, Harvard, Vancouver, ISO, and other styles

38

Nevzorova, K. V., Yu A. Shpilyukova, N. Yu Abramycheva, A. A. Shabalina, E. Yu Fedotova та S. N. Illarioshkin. "Frontal variant of Аlzheimer's disease". Russian neurological journal 29, № 6 (2025): 56–63. https://doi.org/10.30629/2658-7947-2024-29-6-56-63.

Full text

Abstract:

Alzheimer’s disease (AD) is a chronic neurodegenerative disease, that is the most common cause of dementia. Late on-set AD is usually associated with the classic picture of short-term memory deficits, while early onset AD demonstrates atypical symptoms. The frontal variant is the rarest non-amnestic AD phenotype, which associated with selective neurodegeneration in frontal control networks, which is confirmed by the presence of biomarkers of amyloid pathology. The clinical picture includes a wide variety of symptoms, including disinhibition, apathy, compulsive behavior and executive dysfunctio

APA, Harvard, Vancouver, ISO, and other styles

39

Cerami, Chiara, Alessandra Dodich, Sandro Iannaccone, et al. "A biomarker study in long-lasting amnestic mild cognitive impairment." Alzheimer's Research & Therapy 10, no. 1 (2018): 42. https://doi.org/10.1186/s13195-018-0369-8.

Full text

Abstract:

<strong>Background: </strong>Mild cognitive impairment (MCI) is a heterogeneous syndrome resulting from Alzheimer's disease (AD) as well as to non-AD and non-neurodegenerative conditions. A subset of patients with amnestic MCI (aMCI) present with an unusually long-lasting course, a slow rate of clinical neuropsychological progression, and evidence of focal involvement of medial temporal lobe structures. In the present study, we explored positron emission tomography (PET) and cerebrospinal fluid (CSF) biomarkers in a sample of subjects with aMCI with such clinical features in order to provide i

APA, Harvard, Vancouver, ISO, and other styles

40

Phillips, Jeffrey S., Nagesh Adluru, Moo K. Chung, et al. "Greater white matter degeneration and lower structural connectivity in non-amnestic vs. amnestic Alzheimer’s disease." Frontiers in Neuroscience 18 (March 18, 2024). http://dx.doi.org/10.3389/fnins.2024.1353306.

Full text

Abstract:

IntroductionMultimodal evidence indicates Alzheimer’s disease (AD) is characterized by early white matter (WM) changes that precede overt cognitive impairment. WM changes have overwhelmingly been investigated in typical, amnestic mild cognitive impairment and AD; fewer studies have addressed WM change in atypical, non-amnestic syndromes. We hypothesized each non-amnestic AD syndrome would exhibit WM differences from amnestic and other non-amnestic syndromes.Materials and methodsParticipants included 45 cognitively normal (CN) individuals; 41 amnestic AD patients; and 67 patients with non-amnes

APA, Harvard, Vancouver, ISO, and other styles

41

Abbate, Carlo, Pietro D. Trimarchi, Giorgio G. Fumagalli, et al. "Diencephalic versus Hippocampal Amnesia in Alzheimer’s Disease: The Possible Confabulation-Misidentification Phenotype." Journal of Alzheimer's Disease, November 21, 2022, 1–26. http://dx.doi.org/10.3233/jad-220919.

Full text

Abstract:

Background: Alzheimer’s disease (AD) is clinically heterogeneous, including the classical-amnesic (CA-) phenotype and some variants. Objective: We aim to describe a further presentation we (re)named confabulation-misidentification (CM-) phenotype. Methods: We performed a retrospective longitudinal case-series study of 17 AD outpatients with the possible CM-phenotype (CM-ADs). Then, in a cross-sectional study, we compared the CM-ADs to a sample of 30 AD patients with the CA-phenotype (CA-ADs). The primary outcome was the frequency of cognitive and behavioral features. Data were analyzed as diff

APA, Harvard, Vancouver, ISO, and other styles

42

Abdi, Z., K. X. Yong, J. M. Schott, et al. "Pathological Characterisation of Posterior Cortical Atrophy in Comparison With Amnestic Alzheimer's Disease." Neuropathology and Applied Neurobiology 51, no. 2 (2025). https://doi.org/10.1111/nan.70007.

Full text

Abstract:

ABSTRACTAimsPosterior cortical atrophy (PCA) is a predominantly young‐onset neurodegenerative syndrome, typically caused by Alzheimer's disease (PCA‐AD). PCA‐AD presents with visual and spatial dysfunction attributed to occipito‐parietal or ‘posterior’ brain regions rather than memory difficulties characteristic of typical amnestic‐led Alzheimer's disease (a‐AD) attributed to medial temporal regions. Imaging and neuropathological studies suggest that PCA‐AD is associated with a more posterior distribution of tau neurofibrillary tangles (NFTs), whereas β‐amyloid pathology (Aβ) is diffusely depo

APA, Harvard, Vancouver, ISO, and other styles

43

Lingenberg, Alma, François R. Herrmann, Stéphane Armand, Julie Péron, Frédéric Assal, and Gilles Allali. "Forget About Memory: Disentangling the Amnestic Syndrome in Idiopathic Normal Pressure Hydrocephalus." Journal of Alzheimer's Disease, September 19, 2024, 1–12. http://dx.doi.org/10.3233/jad-240439.

Full text

Abstract:

Background: Idiopathic normal pressure hydrocephalus (iNPH) can present with both episodic amnestic syndrome and biomarkers of Alzheimer’s disease (AD) pathology. Objective: To examine the associations between amnestic syndrome and cerebrospinal fluid (CSF) AD biomarkers in iNPH and the CSF tap test response in iNPH patients with amnestic syndrome. Methods: We used the Free and Cued Selective Reminding Test to divide iNPH into amnestic and non-amnestic patients. We compared their clinical, biological, and radiological characteristics and examined the reversibility of gait spatiotemporal parame

APA, Harvard, Vancouver, ISO, and other styles

44

Cousins, Katheryn A. Q., Jeffrey S. Phillips, Sandhitsu R. Das та ін. "Combining plasma biomarkers for β‐amyloid diagnosis and cognitive prognosis across the clinical spectrum: normal, amnestic, and non‐amnestic". Alzheimer's & Dementia 20, S2 (2024). https://doi.org/10.1002/alz.085075.

Full text

Abstract:

AbstractBackgroundAlzheimer’s disease (AD) is clinically heterogeneous, and can manifest as amnestic or non‐amnestic dementia, or be pre‐manifest in persons with normal cognition (NormCog). Utility of plasma biomarkers to diagnose AD and prognose cognitive decline must be evaluated in a clinically heterogeneous population representative of the AD spectrum. We investigate pathological and cognitive correlates of plasma phosphorylated tau 181 (p‐tau181), glial fibrillary acidic protein (GFAP), and neurofilament light chain (NfL) across AD and AD‐related dementias (ADRD). We test 1.) if combing b

APA, Harvard, Vancouver, ISO, and other styles

45

De Keersmaecker, Sebastiaan, Steffi De Meyer, and Rik Vandenberghe. "Non‐Alzheimer's amnestic mild cognitive impairment with medial temporal hypometabolism." Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring 16, no. 4 (2024). http://dx.doi.org/10.1002/dad2.70018.

Full text

Abstract:

AbstractINTRODUCTIONThe increasing use of Alzheimer's disease (AD) biomarkers has led to the recognition of a subgroup of non‐AD amnestic mild cognitive impairment (aMCI) patients who have medial temporal hypometabolism on fluorodeoxyglucose‐positron emission tomography (FDG‐PET).METHODSIn this academic memory‐clinic‐based consecutive series, 16 non‐AD aMCI patients and 28 AD controls matched for sex, age, and baseline Mini‐Mental State Examination (MMSE) were followed for a median duration of 4.5 years. Our primary outcome was the MMSE decline rate over the subsequent years. We also determine

APA, Harvard, Vancouver, ISO, and other styles

46

Lalive, Hadrien M., Alessandra Griffa, Sabrina Carlier, et al. "Amnestic Syndrome in Memory Clinics: Similar Morphological Brain Patterns in Older Adults with and without Alzheimer’s Disease." Journal of Alzheimer's Disease, June 7, 2024, 1. http://dx.doi.org/10.3233/jad-240026.

Full text

Abstract:

Background: Amnestic syndrome of the hippocampal type (ASHT) in Memory Clinics is a presentation common to Alzheimer’s disease (AD). However, ASHT can be found in other neurodegenerative disorders. Objective: To compare brain morphometry including hippocampal volumes between amnestic older adults with and without AD pathology and investigate their relationship with memory performance and cerebrospinal fluid (CSF) biomarkers. Methods: Brain morphometry of 92 consecutive patients (72.5±6.8 years old; 39% female) with Free and Cued Selective Recall Reminding Test (FCSRT) total recall < 40/48 w

APA, Harvard, Vancouver, ISO, and other styles

47

Minogue, Grace, Allegra Kawles, Antonia Zouridakis, et al. "Distinct Patterns of Hippocampal Pathology in Alzheimer's Disease with TDP‐43." Annals of Neurology, August 18, 2023. http://dx.doi.org/10.1002/ana.26762.

Full text

Abstract:

ObjectiveAge‐related dementia syndromes are often not related to a single pathophysiologic process, leading to multiple neuropathologies found at autopsy. An amnestic dementia syndrome can be associated with Alzheimer's disease (AD) with comorbid TDP‐43 pathology (AD/TDP). Here, we investigated neuronal integrity and pathologic burden of TDP‐43 and tau along the well‐charted trisynaptic hippocampal circuit [dentate gyrus (DG), CA3, and CA1] in participants with amnestic dementia due to AD/TDP, amnestic dementia due to AD alone, or non‐amnestic dementia due to TDP‐43 proteinopathy associated wi

APA, Harvard, Vancouver, ISO, and other styles

48

Fernandez, Paulo Eduardo Lahoz, Ivy Liger, Nayara Christina de Lima Curti, Marisa Macedo Kuenzer Bond, Mariana Braga Falcão, and Paulo Henrique Ferreira Bertolucci. "Synergistic role of white matter changes and CSF biomarkers in amnestic and non‐amnestic AD phenotypes." Alzheimer's & Dementia 19, S15 (2023). http://dx.doi.org/10.1002/alz.075891.

Full text

Abstract:

AbstractBackgroundAlzheimer’s disease (AD) is pathologically diagnosed based on abnormal amyloid and tau pathology but is also related to additional pathologic processes. (1) The cognitive symptoms are not directly associated with AD pathology but are the consequence of a complex mechanism, showing discordance between clinical symptoms and CSF biomarkers. (2) Previous evidence suggests a range from the synergistic role of white matter signal abnormality (WMSA) and CSF biomarkers on AD to no relationship between the two. (1) We aimed to analyze the CSF biomarker profiles, and brain MRI changes

APA, Harvard, Vancouver, ISO, and other styles

49

Cacciamani, Federica, Marion Houot, Geoffroy Gagliardi, et al. "Awareness of Cognitive Decline in Patients With Alzheimer's Disease: A Systematic Review and Meta-Analysis." Frontiers in Aging Neuroscience 13 (August 3, 2021). http://dx.doi.org/10.3389/fnagi.2021.697234.

Full text

Abstract:

Background: Identifying a poor degree of awareness of cognitive decline (ACD) could represent an early indicator of Alzheimer's disease (AD).Objectives: (1) to understand whether there is evidence of poor ACD in the pre-dementia stages of AD; (2) to summarize the main findings obtained investigating ACD in AD; (3) to propose a conceptual framework.Data Sources: We searched Scopus, Pubmed, and the reference lists for studies published up to August 2020. Original research articles must report a measure of ACD and included individuals with AD dementia, or prodromal AD (or MCI), or being at risk f

APA, Harvard, Vancouver, ISO, and other styles

50

Briggs, Anthony Q., Rebecca A. Betensky, Mark A. Bernard, and Arjun V. Masurkar. "The Association between measures of Sleepiness and Subjective Cognitive Decline symptoms in a diverse population of cognitively normal older Adults." Alzheimer's & Dementia 20, S9 (2024). https://doi.org/10.1002/alz.093993.

Full text

Abstract:

AbstractBackgroundSubjective cognitive decline (SCD) is a preclinical stage of Alzheimer’s disease (AD), with correlations to cerebral amyloid and tau and accelerated cognitive decline. Studies have also revealed an association between sleep fragmentation and such AD biomarkers and cognitive decline, suggesting that cognitive function should be monitored in individuals experiencing excessive sleepiness. It is unclear if and how sleep dysfunction relates to SCD apart from AD biomarkers, as well as symptoms related to SCD and sleep dysfunction, such as depression. Furthermore, studies of SCD and

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!